Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

PILA PHARMA

3.1

 

SEK

 

-1.9 %

Less than 1K followers

PILA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership

PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the painful rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.

Read more
Market cap
84.09M SEK
Turnover
4.91K SEK
Revenue
780K
EBIT %
-1,039.74 %
P/E
-
Dividend yield-%
-
Financial calendar
27/8
2025

Interim report Q2'25

All
Webcasts
Press releases
ShowingAll content types
Press releaseyesterday

PILA PHARMA INVITES TO AFTER-WORK MINGLE IN STOCKHOLM

PILA PHARMA
Press releaseyesterday

PILA PHARMA UPCOMING INVESTOR PRESENTATIONS IN STOCKHOLM

PILA PHARMA
Press release6/10/2025, 9:01 AM

PILA PHARMA DISCUSSED ITS POTENTIAL ROLE IN OBESITY & DIABETES WITH HELGE LARSEN & PROINVESTOR

PILA PHARMA

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/4/2025, 2:15 PM

PILA PHARMA TO RE-VISIT PROINVESTOR WITH HELGE LARSEN TO DISCUSS THE COMPANY'S AMBITIONS IN OBESITY & DIABETES

PILA PHARMA
Regulatory press release4/30/2025, 6:30 AM

PILA PHARMA PROACTIVELY MOVES FORWARD WITH PP-CT03 CLINICAL TRIAL APPLICATION FOR STUDY IN PEOPLE LIVING WITH OBESITY AND DIABETES

PILA PHARMA
Regulatory press release4/29/2025, 2:15 PM

KOMMUNIKÉ FRÅN ÅRSSTÄMMA I PILA PHARMA AB 2025

PILA PHARMA
Press release4/25/2025, 3:00 PM

PILA PHARMA UPCOMING INVESTOR MEETINGS

PILA PHARMA
Press release4/23/2025, 1:28 PM

PILA PHARMA: REMINDER - LAST DAY FOR SHAREHOLDER REGISTRATION FOR ANNUAL GENERAL MEETING

PILA PHARMA
Regulatory press release3/27/2025, 9:00 AM

KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB

PILA PHARMA
Regulatory press release3/27/2025, 7:30 AM

PILA PHARMA PUBLISHES THE ANNUAL REPORT 2024

PILA PHARMA
Regulatory press release2/27/2025, 7:00 AM

PILA PHARMA PUBLISHES YEAR-END REPORT (1 JANUARY - 31 DECEMBER 2024)

PILA PHARMA
Press release2/24/2025, 3:45 PM

PILA PHARMA INVITES TO H2 REPORT WEBINAR & INVESTOR Q&A

PILA PHARMA
Regulatory press release12/18/2024, 2:00 PM

PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY

PILA PHARMA
Press release12/13/2024, 10:36 AM

PILA PHARMA ANNOUNCES NEW CHIEF FINANCIAL OFFICER (CFO)

PILA PHARMA
Press release11/21/2024, 9:00 AM

PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE

PILA PHARMA
Press release11/20/2024, 4:00 PM

PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS

PILA PHARMA
Press release11/19/2024, 11:03 AM

PILA PHARMA AB Chairman & CEO increase their holdings

PILA PHARMA
Press release11/14/2024, 7:50 AM

PILA PHARMA TO PARTICIPATE IN DANISH INVESTMENT PODCAST "MILLIONÆRKLUBBEN"

PILA PHARMA
Regulatory press release11/14/2024, 7:00 AM

PILA PHARMA ANNOUNCES SELECTION OF CLINICAL TRIAL SITE AND DECISION TO SEEK SCIENTIFIC ADVICE FOR OPTIMIZED PP-CT03 STUDY DESIGN

PILA PHARMA
Regulatory press release11/13/2024, 7:00 AM

PILA PHARMA ANNOUNCES PROGRESSION AND CO-SPONSORSHIP OF PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE

PILA PHARMA
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team